SCHEMBL13184263

SCHEMBL13184263

Cc1cc(C(=O)c2cc(C)n(C)n2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BAZ2B Q9UIF8 1/20 0.47
▸ PROKR1 Q8TCW9 1/20 0.40
▸ KDM4E B2RXH2 5/20 0.39
▸ GAA P10253 3/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ ENPP3 O14638 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ XIAP P98170 1/20 0.38
▸ NR2E1 Q9Y466 2/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ CCR9 P51686 1/20 0.37
▸ RORA P35398 1/20 0.36
▸ JMJD6 Q6NYC1 2/20 0.36
▸ KDM5A P29375 3/20 0.36
▸ KDM4C Q9H3R0 3/20 0.36
▸ KDM5B Q9UGL1 3/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16200409 0.79 BAZ2B (0.47) BAZ2BKDM4EGAARAB9AKMT2A
SCHEMBL3356107 0.78 UHRF1 (0.50) PROKR1KDM4ERAB9AKMT2ANPC1
SCHEMBL27787704 0.78 BAZ2B (0.66) BAZ2BKDM4EGAARAB9AKMT2A
SCHEMBL13184258 0.78 BAZ2B (0.53) BAZ2BKDM4EGAARAB9AKMT2A
SCHEMBL13184401 0.77 KDM4E (0.39) PROKR1KDM4EGAAKMT2AENPP3
SCHEMBL16200404 0.75 POLB (0.43) PROKR1KDM4EGAARAB9AKMT2A
SCHEMBL13683131 0.75 GRM5 (0.42) PROKR1KDM4EGAAENPP3ALPL
SCHEMBL13184261 0.74 BAZ2B (0.49) BAZ2BKDM4EGAARAB9AKMT2A
SCHEMBL13184426 0.72 GRM5 (0.37) PROKR1KDM4EENPP3ALPLXIAP
SCHEMBL13683139 0.72 GRM5 (0.35) PROKR1KDM4EGAACCR9JMJD6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720545-B1 BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES CHEMOCENTRYX INC (US) 2014-10-29 — — EP disclosed
US-8324216-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2012-12-04 — — US disclosed
US-20100240618-A1 SUBSTITUTED PIPERAZINES CHEMOCENTRYX, INC. (US) 2010-09-23 — — US disclosed
US-7589199-B2 Substituted piperazines CHEMOCENTRYX, INC. (US) 2009-09-15 — — US disclosed
US-7435831-B2 Bicyclic and bridged nitrogen heterocycles CHEMOCENTRYX, INC. (US) 2008-10-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240618-A1 SUBSTITUTED PIPERAZINES CCR1, CCR3, CCRL2 BAZ2B 108/4885PROKR1 221/4885KDM4E 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback